These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28337853)

  • 1. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
    Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
    Mendoza FA; Lee-Ching C; Jimenez SA
    Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
    Nihtyanova SI; Brough GM; Black CM; Denton CP
    Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
    Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
    J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
    Le EN; Wigley FM; Shah AA; Boin F; Hummers LK
    Ann Rheum Dis; 2011 Jun; 70(6):1104-7. PubMed ID: 21378404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
    Herrick AL; Pan X; Peytrignet S; Lunt M; Hesselstrand R; Mouthon L; Silman A; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuţa C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Jobanputra P; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; İnanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Denton CP
    Ann Rheum Dis; 2017 Jul; 76(7):1207-1218. PubMed ID: 28188239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.
    Derk CT; Grace E; Shenin M; Naik M; Schulz S; Xiong W
    Rheumatology (Oxford); 2009 Dec; 48(12):1595-9. PubMed ID: 19846575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.
    Poelman CL; Hummers LK; Wigley FM; Anderson C; Boin F; Shah AA
    J Rheumatol; 2015 Feb; 42(2):236-42. PubMed ID: 25433527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
    Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
    Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
    Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
    Herrick AL; Lunt M; Whidby N; Ennis H; Silman A; McHugh N; Denton CP
    J Rheumatol; 2010 Jan; 37(1):116-24. PubMed ID: 19955050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-associated primary central nervous system lymphoma in a patient with diffuse cutaneous systemic sclerosis on long-term mycophenolate mofetil.
    Chatterjee S; Angelov L; Ahluwalia MS; Yeaney GA
    Joint Bone Spine; 2020 Mar; 87(2):163-166. PubMed ID: 31669807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
    Wannarong T; Muangchan C
    Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma.
    Stratton RJ; Wilson H; Black CM
    Rheumatology (Oxford); 2001 Jan; 40(1):84-8. PubMed ID: 11157146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.